January 8, 2024 01:36 PM ESTUpdated 02:09 PM

Updated: Novartis close to acquiring Cytokinetics after biotech's PhIII heart disease win — WSJ

Novartis is in discussions to buy Cytokinetics, the Wall Street Journal reported Monday, sending the biotech’s stock $CYTK soaring nearly 15 …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Up­dat­ed: No­var­tis close to ac­quir­ing Cy­to­ki­net­ics af­ter biotech's PhI­II heart dis­ease win — WSJ